DIPG-45. Radiation induces a robust interferon response in Diffuse Midline Glioma (DMG), improving the potential for combination immunotherapy

Diffuse Midline Glioma (DMG), H3K27M altered, confers a dismal survival of 9-15 months and has a non-inflammatory tumor immune microenvironment (TIME). Radiation therapy (RT) is the mainstay treatment for DMG and has been shown in other cancers to recruit an immune component. However, the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: Minns, Hanna E, Padilla, Oscar, Wei, Hong-Jian, Webster-Carrion, Andrea, Tazhibi, Masih, McQuillan, Nicholas, Zhang, Xu, Yeh, Rebecca, Zhang, Zhiguo, Szalontay, Luca, Pavisic, Jovana, Garty, Guy, Garvin, James, Zacharoulis, Stergios, Canoll, Peter, Vanpouille-Box, Claire I, Menon, Vilas, Olah, Marta, Rabadan, Raul, Wu, Cheng-Chia, Gartrell, Robyn D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Diffuse Midline Glioma/DIPG
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164968/
http://dx.doi.org/10.1093/neuonc/noac079.102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164968/
http://dx.doi.org/10.1093/neuonc/noac079.102

Ejemplares similares